Clinical Trials Logo

Clinical Trial Summary

To compare the efficacy and safety of NPB-01 in patients with autoimmune encephalitis refractory to steroid pulse therapy using steroid pulse therapy as a control.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05177939
Study type Interventional
Source Nihon Pharmaceutical Co., Ltd
Contact Mamoru Ota
Phone 03-5148-7574
Email kaihatsu@nihon-pharm.co.jp
Status Recruiting
Phase Phase 3
Start date March 3, 2022
Completion date October 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT05645185 - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
Completed NCT04708626 - Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting NCT04106596 - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Not yet recruiting NCT05711563 - Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Completed NCT04175522 - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: Phase 2
Recruiting NCT03194815 - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 Phase 2
Recruiting NCT06079294 - Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism N/A
Not yet recruiting NCT03957616 - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed NCT02905136 - Mechanisms of Auto-immune Encephalitis
Recruiting NCT05280600 - Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Recruiting NCT06173076 - A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Recruiting NCT03993262 - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis Phase 2
Recruiting NCT06033846 - Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis Phase 2
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Active, not recruiting NCT06432803 - Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
Recruiting NCT06019975 - FDG-PET in the Diagnosis of Autoimmune Encephalitis
Completed NCT05783947 - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Not yet recruiting NCT06456736 - Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
Completed NCT05825690 - BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis